Colivelin (intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42[1].
Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21 mL; on the Y-maze testday) suppresses memory impairment caused by 3-quinuclidinyl benzilateand restricts functional memory deficit[1].
Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test.It also reduces lesion volume and improves neurological deficits after MCAO[3].
| Animal Model: | CD-1 mice[1] |
| Dosage: | 10 pmol/3 μl |
| Administration: | Intracerebroventricular administration |
| Result: | Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons. |
| Animal Model: | C57 mice[1] |
| Dosage: | 1.4, 7, or 35 nM/0.21mL |
| Administration: | Intraperitoneal administration |
| Result: | Protected against cholinotoxin-induced amnesia in mice. |
| Animal Model: | Male C57BL/6 mice[3] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal administration |
| Result: | Protected against ischemic brain injury, and improves neurological outcomes |
